Caris Life Sciences, an artificial intelligence-driven "TechBio" company focused on precision oncology and molecular profiling, is a stock rather than an ETF. Founded in 2008 and headquartered in Irving, Texas, the company develops molecular diagnostic tests that help match cancer patients to targeted therapies, alongside pharmaceutical research services. The $40 stock price target matters because it sits just below the stock's prior 52-week high near $42.50 and represents a round, psychologically significant milestone that earlier analyst calls, including targets of $40 and $42, helped popularize.
CAI shares recently traded near $25, well below their earlier peak. Over the past year the stock has swung widely, ranging from roughly $14 to $42.50, reflecting both the excitement surrounding AI-enabled healthcare and the volatility that followed. The company's market capitalization is approximately $7 billion, and its business has been expanding rapidly. Third-quarter 2025 revenue of $216.8 million rose 113% year over year, and preliminary full-year 2025 revenue reached about $800 million, up roughly 94%. Gross margins improved materially, climbing from around 43.7% to approximately 68%, and the company reported positive adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) of about $51.2 million in the third quarter of 2025, with a cash position near $760 million.
Several factors could support a move toward $40. Continued double-digit revenue growth from the company's tissue-based MI Profile and blood-based Caris Assure therapy-selection tests is the core engine. Expanding gross margins toward 60% or higher would strengthen the profitability story. The company is also advancing newer products, including Caris Detect, a multi-cancer early detection test being commercialized through a partnership with Everlywell, expected to become available in 2026. A meaningful ramp in these pipeline products, combined with sustained case-volume growth in its core diagnostics, could re-rate the stock and push it back toward prior highs.
The path to $40 is not straightforward. The stock trades at a premium relative to many traditional diagnostics peers, and analysts have repeatedly lowered their targets as shares pulled back. Canaccord Genuity has maintained a Hold rating, trimming its target from $30 to $22, while JPMorgan cut its objective from $35 to $30 despite an Overweight rating. Competition in precision oncology is intense, with rivals such as Tempus AI (TEM), Guardant Health (GH), Exact Sciences (EXAS), and Natera (NTRA) all vying for the same testing market. Profitability also remains a work in progress, and newer tests like Caris Detect are not expected to contribute material revenue in the near term, meaning the stock currently leans heavily on the growth of its established products.
Wall Street's view has moderated over time. Early coverage included bullish objectives of $40 from Evercore ISI, $42 from Citigroup, and $45 from BTIG, but many of these figures have since been reduced. More recent consensus targets have clustered in the high-$20s to low-$30s, though some firms retain higher figures. This spread underscores the central tension: the underlying business is growing quickly, but the market has not yet assigned consistent credit for that growth. Reaching $40 would likely require analysts to resume raising targets rather than cutting them, which in turn depends on sustained beat-and-raise quarters.
From a technical analysis perspective, $40 acts as a clear resistance level because it sits just beneath the prior 52-week high near $42.50, an area where selling pressure previously emerged. On the downside, the stock's earlier trough near $14 represents a major support zone, with intermediate levels in the low-$20s where the stock has found buyers more recently. A durable recovery would likely need to first reclaim the mid-$30s before any test of $40 becomes realistic, as those levels mark supply zones from earlier declines.
For investors tracking whether CAI can build the momentum required to approach $40, monitoring changing market conditions is essential. Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously scan thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on shifting technical behavior and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and identify emerging trends more efficiently than manual screening allows. Exploring these signals can help investors stay informed as CAI's technical and fundamental picture evolves.
A return to $40 for Caris Life Sciences is realistic over a longer timeframe but far from guaranteed. The strongest support comes from exceptional revenue growth, expanding margins, a large cash cushion, and a pipeline of new products. The primary risks are a still-premium valuation, recurring analyst target reductions, intense competition, and the fact that several promising tests have yet to prove their commercial contribution. Investors should monitor quarterly revenue and case-volume trends, gross margin progression, any update on the Caris Detect rollout, and whether analysts begin raising rather than lowering price objectives. Without a re-acceleration in momentum, $40 is likely to remain out of reach in the near term; with it, the level is well within the range the stock has already demonstrated it can trade.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CAI has been loosely correlated with BMEA. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if CAI jumps, then BMEA could also see price increases.
| Ticker / NAME | Correlation To CAI | 1D Price Change % | ||
|---|---|---|---|---|
| CAI | 100% | +1.25% | ||
| BMEA - CAI | 38% Loosely correlated | +2.35% | ||
| RXRX - CAI | 35% Loosely correlated | +1.27% | ||
| TWST - CAI | 34% Loosely correlated | +0.29% | ||
| TECH - CAI | 34% Loosely correlated | +0.06% | ||
| BNTC - CAI | 34% Loosely correlated | -0.25% | ||
More | ||||